The Institute of Bioorganic Chemistry offers consumers a medicinal product - the antitumor drug Leicladin under a manufacturing agreement, a technology for obtaining a substance under a license agreement, and is looking for partners to conclude a distribution services agreement.

Leucladin (pharmaceutical substance and drug) - a broad-spectrum antitumor drug. One of the most effective drugs for treating patients with hairy cell leukemia, chronic lymphocytic leukemia, non-Hogins lymphoma of low and intermediate grade of malignancy. The drug is also used in the treatment of multiple sclerosis.

Import substitution technology. In the original domestic technology for the production of Leukladin, the key chemical stages are replaced by enzymatic ones.

Tests of Leukladin in clinics of Belarus and Russia have shown its high efficiency in the treatment of a number of oncological diseases, as well as in the treatment of multiple sclerosis. Since 2002, the drug has been successfully used in leading clinics in Belarus and Russia.

Patent of the Republic of Belarus No. 5602

The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents, and pesticides to manufacturers.

Consumers interested in purchasing the anticancer drug Leicladin under a manufacturing agreement.

Distributors interested in purchasing the anticancer drug Leicladin under a distribution services agreement.

Partners interested in acquiring technology for obtaining the substance of the anticancer drug Leicladin under a license agreement.